GlassScriptPhysician profile
Renata Zelvyte
NPI 1821455999
$7,710.20
in general payments reported to CMS, 2019-2025
15 companies · $2,201 in 2025
The $2,201 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,329 · 2022: $1,303 · 2023: $1,153 · 2024: $1,724 · 2025: $2,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,075 · Education: $3.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,074.54 |
| Education | $3.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,274.36 | 2021-2025 | Caplyta |
| Alkermes, INC. | $1,127.96 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $878.48 | 2021-2025 | Invega Sustenna |
| Abbvie INC. | $816.48 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $680.55 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $612.81 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $540.87 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Lundbeck LLC | $503.76 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| E.R. Squibb & Sons, L.L.C. | $371.22 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $285.14 | 2021-2022 | |
| Indivior INC. | $271.46 | 2021-2024 | Perseris |
| Janssen Scientific Affairs, LLC | $123.79 | 2025 | Invega Sustenna |
| Vanda Pharmaceuticals INC. | $108.08 | 2022-2025 | Fanapt, Hetlioz |
| Eisai INC. | $62.65 | 2021 | |
| Axsome Therapeutics, INC. | $52.59 | 2024 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renata Zelvyte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.